lifestyle.thenyctimes.com

Author: HUTCHMED (China) Limited

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

March 22, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees

March 6, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates

March 5, 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

March 4, 2026
HUTCHMED to Announce 2025 Final Results

February 11, 2026